In this issue:
Baseline characteristics and outcomes of guselkumab in real-world patients
Ixekizumab vs adalimumab for PsA and moderate-to-severe psoriasis
Paradoxical eczema in patients with psoriasis receiving biologics
Dupilumab in adolescents with moderate-to-severe AD
Dupilumab for up to 4 years in adults with moderate-to-severe AD
Extended dupilumab after short-term failure for AD
Therapeutic drug monitoring of biologics in psoriasis
Please login below to download this issue (PDF)